Kalaris Therapeutics (KLRS) Free Cash Flow (2019 - 2026)
Kalaris Therapeutics (KLRS) posted quarterly Free Cash Flow of -$12.4 million for Q1 2026, down 67.45% year-over-year from -$38.1 million in Q1 2025, and down 79.14% quarter-over-quarter from -$6.9 million in Q4 2025.
Kalaris Therapeutics (KLRS) Free Cash Flow (2019 - 2026) Analysis & Trends
Kalaris Therapeutics' Free Cash Flow history runs 8 years deep, the most recent figure standing at -$12.4 million for Q1 2026.
- In Q1 2026, Free Cash Flow fell 67.45% year-over-year to -$12.4 million; the TTM figure through Mar 2026 stood at -$43.3 million (down 79.47% YoY), while the FY2025 annual figure was -$38.6 million, down 82.85% from the prior year.
- Free Cash Flow for Q1 2026 stood at -$12.4 million, down from -$6.9 million in the prior quarter.
- The five-year high for Free Cash Flow was -$4.0 million in Q2 2024, with the low at -$46.4 million in Q1 2022.
- The 5-year median for Free Cash Flow is -$12.6 million (2025), against an average of -$19.9 million.
- The sharpest annual moves came in 2024 and 2025: Free Cash Flow soared 86.5% in 2024, then slumped 215.0% in 2025.
- Kalaris Therapeutics' Free Cash Flow stood at -$31.4 million in 2022, then climbed by 1.99% to -$30.8 million in 2023, then jumped by 74.12% to -$8.0 million in 2024, then advanced by 13.29% to -$6.9 million in 2025, then sank by 79.14% to -$12.4 million in 2026.
- Business Quant data shows KLRS's Free Cash Flow at -$12.4 million in Q1 2026, -$6.9 million in Q4 2025, and -$11.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Kalaris Therapeutics | 100.19 Mn | 100.19 Mn | - | -11.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -11.01 Mn |
| Jun 30, 2026 | -11.01 Mn |
| Mar 31, 2026 | -12.39 Mn |
| Mar 31, 2026 | -12.39 Mn |
| Dec 31, 2025 | -6.92 Mn |
| Dec 31, 2025 | -6.92 Mn |
| Sep 30, 2025 | -11.40 Mn |
| Sep 30, 2025 | -11.40 Mn |
| Jun 30, 2025 | -12.60 Mn |
| Jun 30, 2025 | -12.60 Mn |
| Mar 31, 2025 | -7.40 Mn |
| Mar 31, 2025 | -7.40 Mn |
| Dec 31, 2024 | -7.98 Mn |
| Dec 31, 2024 | -7.98 Mn |
| Sep 30, 2024 | -4.76 Mn |
| Sep 30, 2024 | -4.76 Mn |
| Jun 30, 2024 | -4.00 Mn |
| Jun 30, 2024 | -4.00 Mn |
| Mar 31, 2024 | -4.38 Mn |
| Mar 31, 2024 | -4.38 Mn |